1036374-90-9Relevant articles and documents
8-Ethynylxanthines as promising antiproliferative agents, angiogenesis inhibitors, and calcium channel activity modulators
Arsenyan, Pavel,Vasiljeva, Jelena,Domracheva, Ilona,Kanepe-Lapsa, Iveta
, p. 776 - 785 (2020)
[Figure not available: see fulltext.] Synthetic procedures for the preparation of 8-ethynylxanthines by treating 8-bromocaffeine and 8-bromopentoxifylline with terminal acetylenes were elaborated. Certain ethynylxanthine derivatives exhibit high in vitro antiproliferative activity against a panel of cancer cell lines, matrix metalloproteinase and in vitro angiogenesis inhibitory activity. Ca2+ channel blocking and agonist activity of the synthesized ethynylxanthines was discussed based on data obtained on the H9C2, SH-SY5Y, and A7R5 cell lines.
ETHYNYLXANTHINES, PREPARATION AND USE AS CALCIUM ION CHANNEL MODULATORS
-
Page/Page column 15; 21; 22, (2016/10/27)
The present invention relates to novel pharmaceutical compounds, which exhibit ability to act as calcium ion channel modulators, methods for their synthesis and the treatment and/or prevention of various diseases and disorders including deregulated calcium ion channel activity.
8-ethinylxanthine derivatives as selective A2A receptor antagonists
-
Page/Page column 26; 53, (2008/12/06)
The present invention relates to novel 8-ethinylxanthirtes of formula (I), pharmaceutical compositions comprising such compounds, methods for preparing such compounds and methods for using these compounds, alone or in combination with other therapeutic agents for the alleviation, prevention and/or treatment of central nervous system (CNS) diseases, disorders and conditions, such as but not limited to Parkinson's disease.